JVA Avidus Management Group, Inc.

Asantae Holdings International Inc. ("Asantae") (TSX-V: JVA) is pleased to announce that it has acquired the rights to an immune system supplement formula. Asantae plans to unveil this new product under the name Asantae Amune Plus™ later this month.

Amune Plus™ is formulated with two immune system support ingredients -- Ai/E(10)® and Astragalus. Ai/E(10)® is a whey extract derived from cow's milk that has been influenced to create a beneficial and highly focused array of immune communication molecules. These molecules help your body to build new cells, modulate immune function and sustain immune system performance. Astragalus is an herb that has been used for centuries for immune support and balance.

"Amune Plus™ is a great addition to our product line up because it addresses a global health issue that is important to most people, their immunity," says Jeff Jordan, president of Asantae. "Plus, it brings with it many customers and sales representatives that have relied on this product for years and are looking to continue to use it."

The formula was acquired from Health Technology Resources, Inc. and was previously marketed under the name Biomune OSF Plus® by Matol.

"Amune Plus is unique in that it not only contains the proprietary and branded dietary ingredient Ai/E(10)®, which has been shown to support the structure and function of the immune system, but it combines it with an herb that has been used for immunity for centuries," says David Bergsma, President of Health Technology Resources, Inc. "Asantae now possesses an outstanding dietary supplement for the modulated support of innate and adaptive immunity which can create a tremendous opportunity for the company's growth and support of its mission to help improve health worldwide."

About Asantae Holdings International Inc.

Asantae Holdings International Inc. (TSX-V: JVA) is a producer and marketer of innovative nutritional products through direct and network marketing channels. The ingredients in Asantae's products have been shown to reduce chronic low-grade inflammation and oxidative stress which, according to scientific and medical research, are the underlying conditions for most modern epidemic diseases (diabetes, heart disease, obesity, stroke, etc.).

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this press release. This press release contains forward-looking statements that include statements as to the potential of our product, such as "[Amune Plus] brings with it many customers and sales representatives that have relied on this product for years and are looking to continue to use it" and "Asantae now possesses an outstanding dietary supplement for the modulated support of innate and adaptive immunity which can create a tremendous opportunity for the company's growth and support of its mission to help improve health worldwide."

Certain risks and uncertainties such establishing and maintaining affiliate relationships, expanding our business in existing markets and international markets, gaining market acceptance of new products, adverse or negative publicity, limited operating history, reliance on a limited number of products, competition from companies selling similar products, product liability claims and recalls, reliance on outside manufacturing and suppliers, protecting intellectual property, reliance on key personnel, and government regulations and global economic conditions could cause Asantae's actual results to differ materially from those in the forward-looking statements.

For further information Keyvan Taheri CEO Phone: 480-278-8700 Fax: 480-383-6147